Abstract

A perimetastatic capsule is a strong positive prognostic factor in liver metastases, but its origin remains unclear. Here, we systematically quantify the capsule’s extent and cellular composition in 263 patients with colorectal cancer liver metastases to investigate its clinical significance and origin. We show that survival improves proportionally with increasing encapsulation and decreasing tumor-hepatocyte contact. Immunostaining reveals the gradual zonation of the capsule, transitioning from benign-like NGFRhigh stroma at the liver edge to FAPhigh stroma towards the tumor. Encapsulation correlates with decreased tumor viability and preoperative chemotherapy. In mice, chemotherapy and tumor cell ablation induce capsule formation. Our results suggest that encapsulation develops where tumor invasion into the liver plates stalls, representing a reparative process rather than tumor-induced desmoplasia. We propose a model of metastases growth, where the efficient tumor colonization of the liver parenchyma and a reparative liver injury reaction are opposing determinants of metastasis aggressiveness.

Cancer liver metastases can be encapsulated by a fibrotic stroma. Here the authors use digital pathology to generate spatial growth pattern maps of colorectal cancer liver metastasis and show that prognosis depends on the degree of fibrotic encapsulation.

Details

Title
An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver
Author
Fernández Moro, Carlos 1   VIAFID ORCID Logo  ; Geyer, Natalie 2 ; Harrizi, Sara 2 ; Hamidi, Yousra 2 ; Söderqvist, Sara 2 ; Kuznyecov, Danyil 3   VIAFID ORCID Logo  ; Tidholm Qvist, Evelina 4 ; Salmonson Schaad, Media 2 ; Hermann, Laura 2 ; Lindberg, Amanda 5 ; Heuchel, Rainer L. 6   VIAFID ORCID Logo  ; Martín-Bernabé, Alfonso 7 ; Dhanjal, Soniya 8 ; Navis, Anna C. 8   VIAFID ORCID Logo  ; Villard, Christina 9 ; del Valle, Andrea C. 2   VIAFID ORCID Logo  ; Bozóky, Lorand 2 ; Sparrelid, Ernesto 10 ; Dirix, Luc 11   VIAFID ORCID Logo  ; Strell, Carina 12 ; Östman, Arne 7   VIAFID ORCID Logo  ; Schmierer, Bernhard 8   VIAFID ORCID Logo  ; Vermeulen, Peter B. 11 ; Engstrand, Jennie 10   VIAFID ORCID Logo  ; Bozóky, Béla 4 ; Gerling, Marco 13   VIAFID ORCID Logo 

 Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Department of Clinical Pathology and Cancer Diagnostics, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Skåne University Hospital, Department of Clinical Genetics, Pathology and Molecular Diagnostics, Medicinsk Service, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987) 
 Karolinska University Hospital, Department of Clinical Pathology and Cancer Diagnostics, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
 Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457) 
 Karolinska Institutet, Pancreatic Cancer Research Laboratory, Department of Clinical Science, Intervention and Technology, Hudinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institutet, Department of Oncology-Pathology, Solna, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institutet, CRISPR Functional Genomics, SciLifeLab and Department of Medical Biochemistry and Biophysics, Solna, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institutet, Department of Medicine Huddinge, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
10  Karolinska Institutet, Karolinska University Hospital, Department of Clinical Science, Intervention and Technology, Division of Surgery, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
11  Translational Cancer Research Unit (GZA Hospitals and University of Antwerp), Antwerp, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681) 
12  Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443) 
13  Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Theme Cancer, Karolinska University Hospital, 17 176, Solna, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
Pages
5024
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2852874222
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.